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"Bak (and Bax) to the Future" — of 
Primary Melanoma Prognosis?
Martin Leverkus1 and Harald Gollnick1
Bcl-2 proteins either block or activate the “intrinsic” mitochondrial apoptosis path-
way. Loss of expression of proapoptotic Bcl-2 proteins, namely Bax and Bak, in pri-
mary melanomas is associated with a worse long-term prognosis. Consequently, 
inactivation of mitochondrial signaling pathways of apoptosis may not only be a 
prerequisite for melanoma progression but may also hamper therapeutic efforts 
with chemotherapeutic drugs. 
Journal of Investigative Dermatology (2006) 126, 1212–1214. doi:10.1038/sj.jid.5700239
Despite major efforts to improve diag-
nosis and stage-specific therapy, the 
incidence of melanoma and its mortality 
rates have increased continuously over 
the past two decades. Unfortunately, 
the prognosis of melanoma patients 
with progressive disease is poor, in par-
ticular for patients with thick lesions or 
regional lymph node metastasis. For 
these patients, there is no general agree-
ment among dermato-oncologists about 
evidence-based treatment modalities 
(Queirolo et al., 2005). Extensive studies 
during the past years have clarified that 
alterations within physiological signaling 
cascades of melanoma cells may be of 
utmost importance for the understanding 
of drug resistance mechanisms and con-
sequently for clinical outcome following 
treatment (Soengas and Lowe, 2003). 
One major challenge is the definition of 
wider arrays of prognostic parameters for 
melanoma after surgical excision of the 
primary tumor, which may subsequently 
justify prognosis-adapted treatment regi-
mens for the patient. This strategy in turn 
may rely on information gained from 
the primary melanoma about signal-
ing pathways activated or silenced dur-
ing melanomagenesis (for review see 
Chudnovsky et al., 2005). One decisive 
factor for successful tumor therapy is 
the initiation of the cell-intrinsic apop-
totic program that is largely dependent 
on activation of the central executioners 
of apoptosis, the caspases (Lavrik et al., 
2005). Their activity is critical not only 
for successful tumor-cell death but also 
for the mounting of a tumor-specific 
immune response (Casares et al., 2005). 
Thus the understanding of apoptosis 
signaling in melanoma may ultimately 
result in better treatment strategies for 
this deadly tumor.
Apoptosis is tightly regulated in a 
cell-specific manner by multiple signal-
ing pathways that interact in successive 
and interconnected amplification loops, 
finally resulting in cell demise. In this 
issue, Fecker et al. (2006) have tackled 
the task of identifying novel prognos-
tic markers in primary melanomas by 
expression analysis of several pro- and 
antiapoptotic proteins in vivo. The authors 
first carefully explored the specificity of 
their immunohistochemical analysis by 
demonstrating positive as well as nega-
tive staining of different tumor samples. 
Upon subdivision of the samples accord-
ing to the presence or absence of clini-
cal progression of these tumors over a 
 follow-up period of 10 years, these 
tumors were investigated for the prognos-
tic relevance of protein expression. What 
type of signals may lead to apoptosis in 
melanoma? In general, apoptotic signal-
ing is broadly divided into “intrinsic” and 
“extrinsic” pathways: the extrinsic path-
way is triggered from the outside of the 
cell by transmembrane proteins called 
death receptors (Locksley et al., 2001). 
These trigger apoptosis by ligand binding 
via recruitment of the initiator caspases 
caspase-8 and/or caspase-10, ultimately 
resulting in activation of effector cas-
pases (for example, caspase-3; Figure 1). 
However, this pathway is tightly regu-
lated by intracellular initiator caspase 
inhibitors such as cFLIP, and this inhibi-
tion seems to be operative in melanoma 
(Bullani et al., 2001). Fecker et al. (2006) 
investigated the protein expression of 
the death receptors DR4 (tumor necrosis 
factor-related apoptosis-inducing ligand-
receptor 1 (TRAIL-R1)) and DR5 (TRAIL-
R2) and important cell cycle regulators 
such as p21 and retinoblastoma pro-
tein, the tumor suppressor p53, and its 
inhibitor MDM2. These studies, although 
performed only in a limited number of 
superficial spreading melanomas (SSMs), 
did not show a significant correlation 
to the prognosis of primary melanoma. 
TRAIL-R1 and TRAIL-R2 were expressed 
in over 90% of primary SSMs, demon-
strating that these two death receptors do 
not predict clinical outcome. However, 
because the death ligand TRAIL or ago-
nistic antibodies to TRAIL-R1 or TRAIL-
R2 are currently undergoing extensive 
preclinical tests for tumor therapy (Kelley 
and Ashkenazi, 2004), these results of 
Fecker et al. (2006), if confirmed in larger 
series of tumors as well as melanoma 
metastasis in vivo, might open a thera-
peutic window for these agents for 
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melanoma treatment. Still, if the reported 
high expression of cFLIP in melanoma 
can be confirmed in larger series (Bullani 
et al., 2001), therapy will require addi-
tional interference with intracellular 
cFLIP-inhibitory pathways by com-
pounds such as small interfering RNAs 
(C Drewniok et al., 2006).
Fecker et al. (2006) then identically 
investigated the expression of a number 
of Bcl-2 family members. The rap-
idly growing Bcl-2 family of proteins, 
for a long time known to control the 
mitochondrial intrinsic cell death path-
way, is currently divided into subgroups 
of molecules with antiapoptotic func-
tion (for example, Bcl-2, Bcl-xl, Bcl-w, 
A1, Mcl-1, and Boo) and proapoptotic 
function (“BH3-only” proteins such as 
Bim, Bid, Bmf, Noxa, and Puma; and 
the subgroup of Bax/Bak-like proteins). 
Current models suggest that the Bax/Bak 
subgroup of molecules (including Bax, 
Bak, Bok, and Bcl-x5), central to the 
proapoptotic function, are held in check 
by the antiapoptotic Bcl-2 proteins. 
These antiapoptotic molecules are in 
turn inactivated by “BH3-only” proteins 
such as Bim, Bid, Bmf, Bik, Noxa, and 
Puma (Figure 1). BH3-only proteins bind 
to a hydrophobic BH3-binding groove 
in antiapoptotic Bcl-2 proteins and are 
currently viewed as crucial sensors of 
cellular stress that regulate the activa-
tion of the intrinsic cell death pathway 
(Strasser, 2005). This pathway is acti-
vated by a plethora of stimuli, including 
cytotoxic drugs, genotoxic stress, growth 
factor withdrawal, DNA damage, 
anchorage loss, and so-called immune 
response modifiers such as imidazoqui-
nolines (Leverkus, 2004). Therefore, Bcl-
2 proteins control a critical checkpoint 
that has to be overcome for efficient 
treatment of cancer cells. Importantly, 
multiple prosurvival proteins must be 
inactivated to unleash proapoptotic Bax 
and Bak, which ultimately drive apop-
tosis via the mitochondria (Cory et al., 
2003). Therefore, strategies to inacti-
vate Bcl-2 family-controlled pathways 
by genetic or epigenetic mechanisms 
might thus protect melanoma cells 
against apoptotic elimination by either 
the immune system or cytotoxic drugs. 
Intriguingly, Fecker et al. (2006) found 
in their study that loss of expression of 
the proapoptotic Bcl-2 family members 
Bax and Bak was significantly correlated 
with SSM prognosis, even though the 
patient collectives did not significantly 
differ in age or Breslow tumor thick-
ness. In contrast, neither Bcl-2, Mcl-1, 
nor Bok was informative with regard to 
patient prognosis. Moreover, tumors that 
had lost both Bax and Bak expression 
were found exclusively in the group of 
SSMs with progression, suggesting that, 
at least in SSM, a Bax/Bak-controlled 
pathway needs to be operative to pre-
vent tumor progression.
Many important questions arise from 
this study. Why is loss of Bax and Bak 
rather confined to SSM? What could be 
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Loss of expression of 
the proapoptotic Bcl-2 
family members Bax and 
Bak was signifi cantly 
correlated with SSM 
prognosis.Figure 1. Bcl-2-controlled apoptosis signaling pathways. In principle, two distinct pathways mediate 
apoptosis, and these converge at the level of activation of effector caspases (for example, caspase-3). 
Extrinsic pathways initiate effector caspase activation directly via initiator caspase-8, which is activated by 
ligation of death receptors. This receptor-proximal activation of caspase-8 is inhibited by cellular FLICE-
inhibitory protein (cFLIP). The intrinsic pathway regulates the release of cytochrome c and other factors 
from mitochondria that are required for caspase-9 activation and/or inhibitor-of-apoptosis protein (IAP) 
inactivation. These signals are tightly controlled by Bcl-2 family members. The antiapoptotic members (for 
example, Bcl-2, Bcl-xl, Bcl-w, A1, Mcl-1, and Boo) probably act by inactivation of proteins of the Bax/Bak 
subfamily (containing Bax, Bak, Bok, and Bcl-xs). Bax/Bak proteins act by multimerization and integration 
into mitochondrial membranes, thereby exerting their proapoptotic function. The “BH3-only” proteins (for 
example, Bim, Bid, Bmf, Noxa, and Puma) most likely act by interfering with the antiapoptotic function 
of distinct subsets of the antiapoptotic Bcl-2 family members. Once activated by initiator caspase-8 or 
caspase-9, active effector caspases then cleave crucial structural protein, and this ultimately leads to full 
cell demolition.
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compounds that circumvent a block of 
the mitochondrial apoptotic signaling 
pathway? Fecker et al. (2006) examined 
a limited panel of metastatic tumors 
and, surprisingly, found not only loss 
of proapoptotic Bax, Bak, and Bok, but 
also loss of antiapoptotic Bcl-2 fam-
ily members such as Bcl-2 and Mcl-1. 
Why are antiapoptotic molecules such 
as Bcl-2 and Mcl-1 downregulated in 
metastatic melanoma? Although at first 
glance counterintuitive, these findings 
might be in line with a recent report that 
antiapoptotic Bcl-2 family members are 
immunogenic (Andersen et al., 2005). 
Thus downregulation of these molecules 
during tumor progression might be 
needed to overcome tumor immune sur-
veillance, and these tumor cells might 
survive only if they also lose expression 
of the proapoptotic Bax and Bak. Of 
note, small molecules that inhibit the 
BH3-binding groove are highly promis-
ing in preclinical testing for solid-can-
cer therapy (Oltersdorf et al., 2005). 
However, the data of Fecker et al. (2006) 
hint at the possibility that melanoma 
treatment would have to circumvent loss 
of Bax and Bak to overcome apoptosis 
resistance. Obviously the studies will 
have to be extended to larger panels of 
tumors and metastases, most interest-
ingly in samples of primary and metas-
tasized tumors in the same individuals. 
Because sentinel lymph node biopsy 
is now widely performed for primary 
melanoma (Ulrich et al., 2004), this infor-
mation may soon be available and might 
confirm whether early loss of Bax or Bak 
is indeed relevant for prognosis at the 
time of primary diagnosis of melanoma. 
Intriguingly, it can be envisioned that, 
beyond being classified solely by histo-
pathological analysis, melanomas may 
be best described on the basis of their 
inactivation profile of distinct signaling 
pathways, and these molecular patterns 
might reflect distinct oncogenic profiles 
(Curtin et al., 2005). In this context, Bax 
and Bak may help us “back to  the future” 
of primary melanoma prognosis.
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Genomic Instability and Tumor Stem 
Cells
James M. Grichnik1
Wang et al. point to the existance of a common progenitor tumor stem cell that 
gives rise to genomically unstable progeny in malignant melanoma. Although it 
is not known what creates this genomic instability, given the presence of testis 
antigens in melanoma, it is tempting to speculate that it is caused by a collision 
of meiotic and mitotic pathways.
Journal of Investigative Dermatology (2006) 126, 1214–1216. doi:10.1038/sj.jid.5700240
Genomic instability is one of the hall-
marks of cancer. Curiously, it is not 
clear whether genomic instability is 
causative or just a ramification of the 
malignant process — or both. In this 
issue, Wang et al. (2006) present data 
from a melanoma patient who experi-
enced apparent complete remissions 
and subsequent recurrences over a 12-
year period. The findings of their study 
point to the existence of a common 
progenitor tumor cell that gives rise to 
genomically unstable progeny.
Wang et al. (2006) karyotyped cells 
from successive melanoma recur-
rences in their patient. The karyo-
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